Advanced search
1 file | 934.30 KB Add to list

The VEGFR inhibitor cediranib improves the efficacy of fractionated radiotherapy in a colorectal cancer xenograft model

(2017) EUROPEAN SURGICAL RESEARCH . 58(3-4). p.95-108
Author
Organization
Keywords
Angiogenesis, Cediranib, Colorectal cancer, In vivo microscopy, Radiotherapy, INTERSTITIAL FLUID PRESSURE, CONTRAST-ENHANCED MRI, RECTAL-CANCER, TUMOR-GROWTH, DOUBLE-BLIND, PHASE-III, BEVACIZUMAB, THERAPY, AZD2171, MICROENVIRONMENT

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 934.30 KB

Citation

Please use this url to cite or link to this publication:

MLA
Melsens, Elodie et al. “The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.” EUROPEAN SURGICAL RESEARCH  58.3-4 (2017): 95–108. Print.
APA
Melsens, E., Verberckmoes, B., ROSSEEL, N., Vanhove, C., Descamps, B., Pattyn, P., & Ceelen, W. (2017). The VEGFR inhibitor cediranib improves the efficacy of fractionated radiotherapy in a colorectal cancer xenograft model. EUROPEAN SURGICAL RESEARCH  , 58(3-4), 95–108.
Chicago author-date
Melsens, Elodie, Bert Verberckmoes, NATACHA ROSSEEL, Christian Vanhove, Benedicte Descamps, Piet Pattyn, and Wim Ceelen. 2017. “The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.” European Surgical Research  58 (3-4): 95–108.
Chicago author-date (all authors)
Melsens, Elodie, Bert Verberckmoes, NATACHA ROSSEEL, Christian Vanhove, Benedicte Descamps, Piet Pattyn, and Wim Ceelen. 2017. “The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.” European Surgical Research  58 (3-4): 95–108.
Vancouver
1.
Melsens E, Verberckmoes B, ROSSEEL N, Vanhove C, Descamps B, Pattyn P, et al. The VEGFR inhibitor cediranib improves the efficacy of fractionated radiotherapy in a colorectal cancer xenograft model. EUROPEAN SURGICAL RESEARCH  . Karger publishers; 2017;58(3-4):95–108.
IEEE
[1]
E. Melsens et al., “The VEGFR inhibitor cediranib improves the efficacy of fractionated radiotherapy in a colorectal cancer xenograft model,” EUROPEAN SURGICAL RESEARCH                                        , vol. 58, no. 3–4, pp. 95–108, 2017.
@article{8502493,
  author       = {Melsens, Elodie and Verberckmoes, Bert and ROSSEEL, NATACHA and Vanhove, Christian and Descamps, Benedicte and Pattyn, Piet and Ceelen, Wim},
  issn         = {0014-312X},
  journal      = {EUROPEAN SURGICAL RESEARCH                                        },
  keywords     = {Angiogenesis,Cediranib,Colorectal cancer,In vivo microscopy,Radiotherapy,INTERSTITIAL FLUID PRESSURE,CONTRAST-ENHANCED MRI,RECTAL-CANCER,TUMOR-GROWTH,DOUBLE-BLIND,PHASE-III,BEVACIZUMAB,THERAPY,AZD2171,MICROENVIRONMENT},
  language     = {eng},
  number       = {3-4},
  pages        = {95--108},
  publisher    = {Karger publishers},
  title        = {The VEGFR inhibitor cediranib improves the efficacy of fractionated radiotherapy in a colorectal cancer xenograft model},
  url          = {http://dx.doi.org/10.1159/000452741},
  volume       = {58},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: